Adjusting meal size and composition resolves this for most people
It refers to retatrutide, a tripleagonist weightloss medication that activates GLP1, GIP, and glucagon receptors. Early clinical trials show unprecedented weightloss results, often greater than currently approved GLP1 and dualagonist drugs, along with improvements in liver fat and metabolic markers. As research advances and more data become available, medically supervised programs will continue to evaluate where TRIPLEagonist medications fit among GLP1 drugs, dualagonists, peptides, and other tools for sustainable metabolic health
Start at 2 mg
Others prefer lower carbohydrate approaches that may enhance Retatrutides fat-burning effects
AMPKalpha2 exerts its anti-inflammatory effects through PARP-1 and Bcl-6
The following information is based on the company's published terms and website as of December 26, 2025